 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| Company type | Subsidiary |
|---|---|
| Nasdaq: CEPH | |
| Industry | Biotechnology, Biopharmaceutical |
| Founded | 1987 |
| Founder |
|
| Headquarters | Frazer, Pennsylvania[citation needed] |
Key people | J. Kevin Buchi (CEO)[when?][citation needed] |
| Products | alertness drug Provigil, the painkiller Actiq, seizure medication Gabitril[1] |
Number of employees | 3,726 (December 31, 2010)[citation needed] |
| Parent | Teva Pharmaceutical Industries |
| Website | www |
Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr.,[1] neuroscientist Michael Lewis, and organic chemist James C. Kauer—all three former scientists with the DuPont Company.[not verified in body] Baldino served as Cephalon's chairman and chief executive officer,[not verified in body] until his death in December 2010.[1] The company's name comes from the adjective "cephalic" meaning "related to the head or brain", as it was established primarily to pursue treatments for neurodegenerative diseases.[not verified in body]
As noted by fundinguniverse.com:
Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms.[2]
Cephalon was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006.[not verified in body] Sales revenues reached $2.8 billion in 2010,[not verified in body] ranking Cephalon among the leading biopharmaceutical companies in the world at that time.[not verified in body]
On May 2, 2011, Teva Pharmaceutical Industries announced it would acquire Cephalon.[3] The deal was completed on October 11, 2011.[4]
- ^ a b c d Meier, Barry (December 21, 2010). "Frank Baldino Jr., Founder of Pharmaceutical Company, Dies at 57". The New York Times. Retrieved November 21, 2018.
- ^ Funding Universe Staff (November 30, 2015). "History of Cephalon, Inc". FundingUniverse.com. Retrieved November 30, 2015.
As a small research house, Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms.
- ^ Teva Staff (May 1, 2011). "טבע רוכשת את Cephalon תמורת 6.8 מיליארד דולר [Teva acquires Cephalon for $ 6.8 billion]" (press release). Teva.co.il. Retrieved February 10, 2020.[better source needed]
- ^ FiecrePharma (October 11, 2011). "Teva Completes Acquisition of Cephalon" (press release). Retrieved March 11, 2024.[better source needed]